Hengel, Richard L.
Schroeder, Claudia P.
Jo, Jinhee
Ritter, Timothy E.
Nathan, Ramesh V.
Gonzales-Luna, Anne J.
Obi, Engels N.
Dillon, Ryan J.
Van Anglen, Lucinda J.
Garey, Kevin W.
Funding for this research was provided by:
merck sharp and dohme corp. (VEAP 6789)
Article History
Received: 6 August 2021
Accepted: 29 April 2022
First Online: 14 May 2022
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by an independent institutional review board and granted exemption for requiring patient consent (IntegReview IRB, Austin, TX, US).
: Not applicable.
: TER is on the advisory boards for Ferring Pharmaceuticals and Rebiotix, Inc. ENO and RJD are current employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. and may own stock and/or stock options in Merck & Co., Inc., Kenilworth, NJ, USA. LVA has received research support from Merck Sharp & Dohme Corp. and is on the advisory board for Ferring Pharmaceuticals. KWG has received research support from Acrux, Summit Pharmaceuticals and is a consultant to Seres Health and Ferring Pharmaceuticals. RLH, CPS, JJ, RVN and AJGL have no potential conflicts of interest.